Lenalidomide-induced elevated bilirubin

Katherine A. Simondsen, Jill M. Kolesar

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Lenalidomide is an immunomodulator used to treat 5q-myelodysplastic syndrome, myelofibrosis, and multiple myeloma. We describe a 55-year-old male who was started on lenalidomide 10 mg daily for 21 days followed by 7 days off therapy for the treatment of early stage post-polycythemia vera myelofibrosis. Following initiation of lenalidomide, the patient was noted to have an asymptomatic increase in unconjugated bilirubin. Alkaline phosphatase, aspartate transaminase, and alanine aminotransferase were normal. During the 7 days off of lenalidomide, bilirubin began to trend down. Re-challenge with lenalidomide in subsequent cycles results in an asymptomatic elevation in unconjugated bilirubin followed by improvement during the 7-day lenalidomide-free period. The patient is a heterozygote for the TA7 allele which can decrease expression of uridine diphosphate glycuronosyl transferase 1A1, the enzyme responsible for conjugation of bilirubin. Therapy with lenalidomide may have unmasked Gilbert's syndrome in the patient.

Original languageEnglish
Pages (from-to)402-405
Number of pages4
JournalJournal of Oncology Pharmacy Practice
Issue number4
StatePublished - Dec 2012


  • Gilbert's syndrome
  • Lenalidomide
  • bilirubin
  • liver enzymes
  • uridine diphosphate glycuronosyl transferase 1A1

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Lenalidomide-induced elevated bilirubin'. Together they form a unique fingerprint.

Cite this